Effects of R type and S type ginsenoside Rg3 on DNA methylation in human hepatocarcinoma cells

SIYING TENG,1,2 YI WANG,1 PINGYA LI,1 JINHUA LIU,1,3 ANHUI WEI,1 HAOTIAN WANG,1 XIANGKUN MENG,1 DI PAN1 and XINMIN ZHANG1

1School of Pharmaceutical Sciences, Jilin University; 2Department of Ophthalmology, First Hospital of Jilin University, Changchun, Jilin 130021; 3Jilin Entry-Exit Inspection and Quarantine Bureau, Changchun, Jilin 130062, P.R. China

Received January 18, 2016; Accepted January 9, 2017
DOI: 10.3892/mmr.2017.6255

Abstract. Ginsenoside Rg3, a bioactive constituent isolated from Panax ginseng, exhibits antitumorigenic, antioxidative, antiangiogenic, neuroprotective and other biological activities associated with the regulation of multiple genes. DNA methylation patterns, particularly those in the promoter region, affect gene expression, and DNA methylation is catalyzed by DNA methylases. However, whether ginsenoside Rg3 affects DNA methylation is unknown. High performance liquid chromatography assay, MspI/HpaII polymerase chain reaction (PCR) and reverse transcription-quantitative PCR were performed to assess DNA methylation. It was demonstrated that 20(S)-ginsenoside Rg3 treatment resulted in increased inhibition of cell growth, compared with treatment with 20(R)-ginsenoside Rg3 in the human HepG2 hepatocarcinoma cell line. It was additionally revealed that treatment with 20(S)-ginsenoside Rg3 reduced global genomic DNA methylation, altered cytosine methylation of the promoter regions of P53, B cell lymphoma 2 and vascular endothelial growth factor, and downregulated the expression of DNA methyltransferase (DNMT) 3a and DNMT 3b more than treatment with 20(R)-ginsenoside Rg3 in HepG2 cells. These results revealed that the modulation of DNA methylation may be important in the pharmaceutical activities of ginsenoside Rg3.

Introduction

Ginsenoside Rg3, which has the chemical name of 12β, 20-dihydroxydammar-24-en-3β-D-glucopyranosyl-D-glucopyranoside, and ginsenoside Rg3 exist in two forms, the R type and S type, according to its asymmetric carbon atom (choral carbon atom) C20. Ginsenoside Rg3 has diverse pharmacological effects in vitro and in vivo via the activation or repression of the expression of different genes. Previous studies have reported that ginsenoside Rg3 inhibits cancer cell proliferation and induces apoptosis by decreasing the expression of histone deacetylase 3 (1), epidermal growth factor receptor (2), fucosyltransferase IV (3) and vascular endothelial growth factor (VEGF) (4), and upregulates the protein expression of pro-apoptotic P53 (1), caspase-3, caspase-8 and caspase-9 (5). Ginsenoside Rg3 has been shown to enhance the radiosensitivity of human esophageal carcinoma cells by downregulating the expression of VEGF and hypoxia inducible factor-1α (6), and ginsenoside Rg3 may have a neuroprotective function in the rat hippocampus via the inhibition of hippocampus-mediated N-methyl-D-aspartate receptor activation (7). Additional biological activities associated with gene regulation have also been demonstrated for this molecule (2,8).

5-methyl-cytosine (m5Cyt) is the most investigated epigenetic modification, and alterations in genomic DNA methylation patterns have been confirmed to be associated with the development of pathological processes and diseases, including cancer (9,10). It has also been reported that DNA methylation patterns can be altered by medication, nutrients and chemicals (11-13). DNA methyltransferases (DNMTs) are enzymes responsible for establishing the original methylation patterns of de novo methylases, DNMT3a and DNMT3b, and for maintaining these throughout subsequent cellular divisions (maintenance methylase DNMT1). However, until now, there have been no reports on whether ginsenoside Rg3 affects DNA methylation or the expression of methyltransferases.

Global hypomethylation and promoter hypermethylation have been found in hepatocarcinogenesis (14-16); therefore, the present study investigated the effects of ginsenoside Rg3 on methylation in the HepG2 human hepatocarcinoma cell line. The results showed that ginsenoside Rg3 inhibited HepG2 cell proliferation in a dose-dependent manner, induced a reduction in global DNA methylation, altered methylated cytosines in the promoter regions of specific genes, upregulated the expression of DNMT1, and downregulated the expression of DNMT3a and DNMT 3b. In addition, the different ginsenoside Rg3 epimers exhibited different biological activities.
Materials and methods

Reagents. High performance liquid chromatography (HPLC)-grade standards for 20(S)-ginsenoside Rg3 and 20(R)-ginsenoside Rg3 were purchased from Shanghai Yuanye Biotechnology Co., Ltd. (Shanghai, China) and dissolved at a concentration of 50 mg/ml in dimethyl sulfoxide as a stock solution (stored at -20°C). This solution was then further diluted in cell culture medium to prepare the working concentrations (0, 7.81, 15.63, 31.25, 62.5, 125, 250 and 500 µg/ml). 5-methyl-2'-deoxyctydine (5-MedC) was purchased from United States Biological (Salem, MA, USA), and 2'-deoxyguanosine (dG), thymidine (T), 2'-deoxyctydite (dC) and 2'-deoxyadenosine (dA) were obtained from Sigma-Aldrich; Merck Millipore (Darmstadt, Germany). Sodium acetate, ammonium formate and acetonitrile were supplied by Beijing Chemical Works (Beijing, China). MNase, nuclease P1 and alkaline phosphatase were purchased from Takara Bio, Inc. (Otsu, Japan).

Analysis of cell viability. Cell proliferation was measured using a Cell Counting Kit-8 (CCK8; Beyotime Institute of Biotechnology, Inc., Jiangsu, China). Briefly, cells of the human hepatocarcinoma cell line HepG2 were cultured in RPMI-1640 supplemented with 10% fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% antibiotics-antimycotics in a humidified 5% CO₂ atmosphere at 37°C. Exponentially growing cells were seeded in a 96-well plate at a density of 1.0x10⁴ cells/well. The following day, the cells were treated in triplicate with the various concentrations of 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3 for 24 h at 37°C. Following incubation for 24 h, cell viability was assessed using the CCK8 assay, according to the manufacturer’s protocol. Finally, the absorbance value was recorded at an optical density of 450 nm (OD₄₅₀) using an enzyme-linked immunosorbent assay plate reader (Emax Plus; Molecular Devices, LLC, Sunnyvale, CA, USA). At least three independent experiments were performed, and the experiments involved three groups: Untreated HepG2 cells (not treated with ginsenoside Rg3), HepG2 cells treated with various concentrations of 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3 as the experimental group, and a blank group of cell culture only. The inhibition rate was calculated using the following formula: (untreated group OD₄₅₀ - treated group OD₄₅₀) x 100%.

Measurement of global DNA methylation using HPLC. HPLC analysis was performed on a liquid chromatograph coupled with a Waters 2489 UV/visible detector (Waters Corporation, Milford, MA, USA). Separation was achieved on a Symmetry® C18 (5 µm; 4.6x250) column (Waters Corporation). The mobile phase consisted of solvent A (50 mM ammonium formate; pH 5.4) and solvent B (HPLC-grade acetonitrile). The following gradient program was used: Solvent B 2% at 0 min, solvent B 3% at 18 min, solvent B 27% at 25 min, solvent B 35% at 40 min and solvent B 2% at 45 min. The total duration of analysis was 50 min. The flow rate was set at 0.2 ml/min and the column oven temperature was maintained at 25°C. UV detection was performed at 277 nm.

The concentrations of MedC and dC were calculated from linear regression curves, and the percentage of methylation was then calculated using the following equation:

\[ \text{5-MedC (\%)} = \frac{[5\text{-MedC]/[dC+MedC]]}{100} \]

Preparation of standards. The 5-MedC, dC, dA, dT and dG stock standard solutions were prepared by diluting purchased powder in appropriate volumes of HPLC grade water. All stock solutions were then mixed at an appropriate ratio to ensure all components were present at the same concentrations: 0.009765, 0.039625, 0.156250, 0.625000, 2.5 and 10 mM for 5-MedC and dC. All standard solutions were stored at -20°C and used within 1 week.

DNA extraction and hydrolysis. Exponentially growing HepG2 cells were seeded at a density 5.0x10⁴ into 75 cm² culture flasks and, following a 24 h period, the cells were either left untreated or were treated with 20(S)-ginsenoside Rg3 or 20(R)-ginsenoside Rg3, in accordance with the cell viability assessment. The cells were then collected, and DNA was purified using a Qiagen DNAeasy® blood and tissue kit (Qiagen GmbH, Hilden, Germany).

Cryonase™ cold-active nuclease (Takara Bio, Inc.), micrococcal nuclease (Takara Bio, Inc.) and digestion buffer comprising 20 mM Tris-HCl, 5 mM NaCl and 2.5 mM CaCl₂ (pH 8.0) were added to the purified DNA and incubated at 37°C overnight. Alkaline phosphatase (calf intestine; 1 unit/ml; Takara Bio, Inc.) was added to the samples, and incubation was continued for an additional 4 h. The hydrolyzed DNA was then centrifuged at 18,000 x g for 20 min at 4°C and adjusted to an appropriate concentration (~4 mM) in HPLC grade water for analysis using HPLC.

MspI/HpaII polymerase chain reaction (PCR) assay. The MspI/HpaII PCR assay was performed as follows: Purified genomic DNA (2 µg) from the control and ginsenoside Rg3-treated samples were digested with 20 units of methylation-sensitive enzymes (MspI or HpaII) in a 20-µl reaction volume using the buffers supplied by the manufacturer (Takara Bio, Inc.). The reaction mixtures were incubated overnight at 37°C. The digested DNA samples were purified with phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform extraction, followed by ethanol precipitation.

PCR was performed with the undigested and digested DNA from the control and ginsenoside Rg3-treated samples. A total of 40 primers were designed based on the sequences of the promoter regions of Homo sapiens B cell lymphoma 2 (Bcl2; NIH accession no. EU119400; www.ncbi.nlm.nih.gov/nuccore/EU119400), Homo sapiens VEGF gene (NIH accession no. AF095785; www.ncbi.nlm.nih.gov/nuccore/AF095785) and Homo sapiens tumor protein P53 (TP53; NIH accession no. NG_017013; www.ncbi.nlm.nih.gov/nuccore/NG_017013). Each set of primers spanned one or more CCGG sites of the target gene. The primer names, primer sequences and positions of the CCGG sequence for each gene are listed in Table 1. Each reaction mixture contained 1 µl DNA (~10 ng), 10 µl Premix Taq™ DNA Polymerase Hot-Start (Takara Bio, Inc.), 1 µl DNA primer (0.5 µM) and 7 µl ddH₂O. The reaction was denatured at 95°C for 5 min, followed by 40 cycles of 95°C
for 15 sec, 55°C for 45 sec and 72°C for 1 min, with a final incubation step at 72°C for 5 min. Following agarose gel electrophoretic separation and staining with ethidium bromide, the amplified products were visualized under UV irradiation. Images were captured for further analysis.

Reverse transcription-quantitative PCR (RT-qPCR) analysis. Total RNA was isolated from the cultured cells using the RNeasy® Mini kit (Qiagen GmbH) according to the manufacturer's protocol. cDNA was synthesized using a ReverTrace qPCR RT kit (ToyoBo Co., Ltd., Osaka, Japan) using an oligo-dT primer, and qPCR was then performed using SYBR®-Green Realtime PCR Master mix (Toyobo Co., Ltd.) with forward and reverse primers for each gene. The sequences of the qPCR primers are listed in Table I. To avoid DNA contamination, at least one primer in each set spanned two exons. Each qPCR reaction mixture contained 1 µl cDNA, 10 µl SYBR® Green Real-Time PCR Master Mix (Toyobo Co., Ltd.), 1 µl DNA primer (0.5 µM) and 7 µl ddH₂O. The PCR was performed in a StepOnePlus™ (Applied Biosystems; Thermo Fisher Scientific, Inc.) with the following thermal cycling protocol: 95°C for 5 min, followed by 40 cycles at 95°C for 15 sec and then at 60°C for 40 sec. The relative expression level of each targeted gene was normalized to the expression of GAPDH calculated using the 2^[-ΔΔCt] quantification method (17).

Statistical analysis. All data were analyzed using descriptive one-way analysis of variance using the SPSS (version 16.0) software package (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference. All data are presented as the mean ± standard deviation.

Results

Antiproliferative effects of 20(S)-ginsenoside Rg3 are more marked, compared with those of 20(R)-ginsenoside Rg3. Ginsenoside Rg3 can exist as either the R type or S type according to its asymmetric carbon atom (Fig. 1). It has been reported that the antiproliferative effects of the different ginsenoside Rg3 epimers are cell line-dependent. Wu et al (18) showed that the tumor inhibition rate achieved by 20(R)-ginsenoside Rg3 was significantly higher, compared with that by 20(S)-ginsenoside Rg3 in hepatoma (H22)-bearing mice. Kim et al (19) found that the antiproliferative effect of 20(S)-ginsenoside Rg3 was higher, compared with that of 20(R)-ginsenoside Rg3 in A549 cells at the same concentration. Park et al (20) reported that 20(S)-ginsenoside Rg3 reduced human gastric cancer cellular proliferation, whereas 20(R)-ginsenoside Rg3 had no effect. Cheong et al (21) showed that 20(S)-ginsenoside Rg3 had higher cytotoxic potency, compared with the 20(R) epimer in HepG2 cells.

The present study confirmed the antiproliferative effects of 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3 on the growth of HepG2 cells using a CCK8 assay, which offers higher sensitivity, compared with an MTT assay. The results (Fig. 2A) showed that treatment of cells with 20(S)-ginsenoside Rg3 over a concentration range of 15.63-500 µg/ml resulted in the inhibition of cellular proliferation, and the antiproliferative effect of 20(R)-ginsenoside Rg3 was observed over a concentration range of 31.25-500 µg/ml. Thus, the two epimers inhibited cellular proliferation in a concentration-dependent manner. As shown in Fig. 2B, the linear regression equation for 20(S)-ginsenoside Rg3 was Y=4.1296X+5.1012 (R²=0.9801) and the linear regression equation for 20(R)-ginsenoside Rg3 was Y=3.2053X+7.9504 (R²=0.9714). From these values, the LD50 of 20(S)-ginsenoside Rg3 was 178.03 µg/ml, whereas that of 20(R)-ginsenoside Rg3 was 326.84 µg/ml. Therefore, treatment with 20(S)-ginsenoside Rg3 resulted in more marked inhibition of cell growth, compared with treatment with 20(R)-ginsenoside Rg3. The doses selected for the treatment of cells in the subsequent experiments were 326.84 µg/ml 20(R)-ginsenoside Rg3 or 178.03 µg/ml 20(S)-ginsenoside Rg3.

Ginsenoside Rg3 induces alterations in DNA methylation globally and in the promoter regions of specific genes. The HPLC method used in the present study was modified from that of Fragou et al (22). In the present study, solvent B was changed from methanamide to acetonitrile, as acetonitrile was found to be more effective. From the HPLC chromatogram of standards, it was found that the C retention time was ~9 min and the 5-MedC retention time was ~16 min (Fig. 3A). The linear regression equation for C was Y=508781X+4356.14 (R²=0.99997; Fig. 3B), and the linear regression equation for MedC was Y=190820X+782.35 (R²=0.99999; Fig. 3B).

The alterations in DNA methylation in the untreated HepG2 cells and HepG2 cells treated with ginsenoside Rg3 are shown in Fig. 4. The data showed that the average DNA methylation was 3.56±0.125% in the untreated cells, 3.36±0.082% in the 20(R)-ginsenoside Rg3-treated cells (P=0.115, vs. untreated group) and 2.66±0.111% in 20(S)-ginsenoside Rg3-treated cells (P=0.0115). The difference between DNA methylation in the 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3 groups was also statistically significant (P=0.0327).

20(R)-ginsenoside Rg3 is known to induce the global hypermethylation of DNA; therefore, the present study examined whether 20(R)-ginsenoside Rg3 affected the methylation of the promoter region of a specific gene. Zhou et al (23) showed that ginsenoside Rg3 can inhibit HepG2 cell proliferation by downregulating the expression of VEGF. Yuan et al (24) reported that the protein expression of anti-apoptotic Bcl2 was downregulated and the protein expression of pro-apoptotic P53 was upregulated by 20(S)-ginsenoside Rg3 in HT-29 colon cancer cells. The present study obtained similar results, which showed that P53 was upregulated, and BCL2 and VEGF were downregulated by treatment of the HepG2 cells with ginsenoside Rg3 (Fig. 5A). Therefore, the present study examined whether the altered gene expression levels were associated with the methylation status of the promoter. The primers used are listed in Table I.

The results of the MspI/HpaII PCR analysis of DNA methylation alterations in BCL2, VEGF and P53 genes induced by ginsenoside Rg3 treatment are shown in Fig. 5. Alterations in DNA methylation at the CGG sequence (2371-2374 bp) were identified in the promoter of BCL2 induced by ginsenoside Rg3, compared with the untreated control. As shown in Fig. 5B, no significant amplification band was detected in the 20(R)-ginsenoside Rg3-treated sample digested by HpaII or MspI, or in the 20(S)-ginsenoside Rg3-treated sample digested...
Table I. Primers.

| Primer | Primer sequence (3'-5')                  | Position (bp) | Gene   | NCBI accession no. |
|--------|------------------------------------------|---------------|--------|--------------------|
| XZ-82  | cagagtacacgtgtctcaacag                  | 1617-1637     | BCL2   | EU119400           |
| XZ-83  | tctagccgttctagagagtgtg                  | 1750-1772     | BCL2   | EU119400           |
| XZ-84  | acacacttcatacactccgtg                   | 1750-1751     | BCL2   | EU119400           |
| XZ-85  | ecggcatgttaaaagaagtgtg                  | 1915-1934     | BCL2   | EU119400           |
| XZ-86  | cagcccgtcttgcctccctcc                  | 1915-1934     | BCL2   | EU119400           |
| XZ-87  | gcctttacagccagcag                      | 2060-2077     | BCL2   | EU119400           |
| XZ-88  | caggegtacgcagagagcag                   | 2060-2077     | BCL2   | EU119400           |
| XZ-89  | gccttgcgtcagaggccag                    | 2154-2169     | BCL2   | EU119400           |
| XZ-90  | gcggaggttcagagaggtgtg                   | 2154-2169     | BCL2   | EU119400           |
| XZ-91  | gtaaaagccgtggctgcag                    | 2250-2268     | BCL2   | EU119400           |
| XZ-92  | gcaccggagcagctggcag                     | 2344-2364     | BCL2   | EU119400           |
| XZ-93  | cagctgttgcacgtgtgc                      | 2528-2544     | BCL2   | EU119400           |
| XZ-94  | caggttcgagcagaggtgtg                    | 2647-2666     | BCL2   | EU119400           |
| XZ-95  | gctttaagcacgagaggtgtg                   | 2724-2745     | BCL2   | EU119400           |
| XZ-96  | gcggaggttcagagaggtgtg                    | 2828-2845     | BCL2   | EU119400           |
| XZ-97  | gcggaggttcagagaggtgtg                    | 2926-2944     | BCL2   | EU119400           |
| XZ-98  | gcggaggttcagagaggtgtg                    | 3006-3028     | BCL2   | EU119400           |
| XZ-99  | gcggaggttcagagaggtgtg                    | 3109-3127     | BCL2   | EU119400           |
| XZ-100 | gcggaggttcagagaggtgtg                    | 3144-3163     | BCL2   | EU119400           |
| XZ-101 | gcggaggttcagagaggtgtg                    | 3206-3208     | BCL2   | EU119400           |
| XZ-102 | gcggaggttcagagaggtgtg                    | 3250-3262     | BCL2   | EU119400           |
| XZ-103 | gcggaggttcagagaggtgtg                    | 3300-3312     | BCL2   | EU119400           |
| XZ-104 | gcggaggttcagagaggtgtg                    | 3344-3364     | BCL2   | EU119400           |
| XZ-105 | gcggaggttcagagaggtgtg                    | 3420-3432     | BCL2   | EU119400           |
| XZ-106 | gcggaggttcagagaggtgtg                    | 3500-3514     | BCL2   | EU119400           |
| XZ-107 | gcggaggttcagagaggtgtg                    | 3570-3582     | BCL2   | EU119400           |
| XZ-108 | gcggaggttcagagaggtgtg                    | 3660-3672     | BCL2   | EU119400           |
| XZ-109 | gcggaggttcagagaggtgtg                    | 3750-3762     | BCL2   | EU119400           |
| XZ-110 | gcggaggttcagagaggtgtg                    | 3850-3862     | BCL2   | EU119400           |
| XZ-111 | gcggaggttcagagaggtgtg                    | 3950-3962     | BCL2   | EU119400           |
| XZ-112 | gcggaggttcagagaggtgtg                    | 4050-4062     | BCL2   | EU119400           |
| XZ-113 | gcggaggttcagagaggtgtg                    | 4150-4162     | BCL2   | EU119400           |
| XZ-114 | gcggaggttcagagaggtgtg                    | 4250-4262     | BCL2   | EU119400           |
| XZ-115 | gcggaggttcagagaggtgtg                    | 4350-4362     | BCL2   | EU119400           |
| XZ-116 | gcggaggttcagagaggtgtg                    | 4450-4462     | BCL2   | EU119400           |
| XZ-117 | gcggaggttcagagaggtgtg                    | 4550-4562     | BCL2   | EU119400           |
| XZ-118 | gcggaggttcagagaggtgtg                    | 4650-4662     | BCL2   | EU119400           |
| XZ-119 | gcggaggttcagagaggtgtg                    | 4750-4762     | BCL2   | EU119400           |
| XZ-120 | gcggaggttcagagaggtgtg                    | 4850-4862     | BCL2   | EU119400           |
Table I. Continued.

| Primer | Primer sequence (3’-5’) | Position (bp) | Gene | NCBI accession no. |
|--------|-------------------------|---------------|------|-------------------|
| XZ-175 | ctggttacactctccactcccac | 5761-5785     | P53  | NG_017013         |
| XZ-176 | gtggaagtgagaagtgctaaaccag | 5761-5785 | P53  | NG_017013         |
| XZ-48  | acagagccagagtgagaag     | 333-352       | DNMT1| AF180682          |
| XZ-49  | ctctctcttctctctctc      | 576-595       | DNMT1| AF180682          |
| XZ-52  | gagaagggcccaagaaacag    | 659-766       | DNMT3a| AF331856         |
| XZ-53  | cttgctcttcgatgtagtag    | 802-823       | DNMT3b| AF331857         |
| XZ-56  | cagagatgagggcagagaa     | 965-984       | DNMT3b| AF331857         |
| XZ-57  | agttctctcagagacctc      | 1132-1151     | DNMT3b| AF331857         |
| XZ-60  | gacctcaacatggtttaa      | 175-195       | GAPDH| M33197           |
| XZ-61  | tgaagggatcctgtagatg     | 264-283       | GAPDH| M33197           |
| XZ-62  | agggctgcttggcttcgctc    | 875-895       | P53  | AB082923         |
| XZ-63  | ctctctctctctctcctcct    | 916-937       | P53  | AB082923         |
| XZ-64  | gctggctacgcctttggaaac   | 2039-2059     | BCL2 | M13994           |
| XZ-65  | tcgagatgagggcgccagagagc | 2102-2122     | BCL2 | M13994           |
| XZ-66  | ccacacattcaccagagatg    | 315-337       | VEGF | AY047581         |
| XZ-67  | Tgctcttccagagatcactcetc | 369-390       | VEGF | AY047581         |

BCL2, B cell lymphoma 2; VEGF, vascular endothelial growth factor; DNMT, DNA methyltransferase.

Figure 1. Chemical structure and HPLC chromatogram of 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3. The X-axis shows the retention time and the Y-axis shows the voltage. The position of the asymmetric carbon atom in ginsenoside Rg3 is marked with a red circle. From the HPLC chromatograms of standards, the 20(R)-ginsenoside Rg3 retention time was ~11.5 min, compared with the 20(S)-ginsenoside Rg3 retention time of 10.5 min. (A) R type; (B) S type. HPLC, high performance liquid chromatography.
TENG et al: EFFECTS OF GINSENOSIDE Rg3 ON DNA METHYLATION

However, a weak specific band was observed in the 20(S)-ginsenoside Rg3-treated sample digested by HpaII. These data indicated that the cytosine demethylation at this site was induced by ginsenoside Rg3, and that 20(R)-ginsenoside Rg3 had a higher potential to induce methylation at this site, compared with 20(S)-ginsenoside Rg3. Alterations in DNA methylation at the CCGG sequence (1,981-1,984 bp) in the VEGF promoter are shown in Fig. 5C. No significant differences were found in the amplification profiles among the three groups, which indicated that the DNA methylation status was not altered following ginsenoside Rg3 treatment. Alterations in DNA methylation at the CCGG sequence (5,641-5,644 bp) in the P53 promoter are shown in Fig. 5D, and an amplification band was found in the untreated control and 20(R)-ginsenoside Rg3-treated sample digested by HpaII, however, no band was observed for the 20(S)-ginsenoside Rg3-treated sample digested by HpaII. These data indicated that DNA methylation was decreased upon treatment with 20(S)-ginsenoside Rg3 at this site, whereas the DNA methylation status remained unchanged (Table II). If the band patterns remained unchanged, compared with those of the untreated control group, it was scored 0. If the patterns showed that cytosine methylation was increased, it was scored 1. If the patterns showed that cytosine methylation
was decreased, it was scored 2. The results of the MspI/HpaII PCR analysis showed that the percentages of CCGG sites remaining unchanged were 52 and 64% following treatment with 20(R)-ginsenoside Rg3 and 20(S)-ginsenoside Rg3, respectively. The percentages of methylated bands were 24 and 16% in the 20(R)-ginsenoside Rg3- and 20(S)-ginsenoside Rg3-treated groups, whereas the percentages of demethylated bands were 24 and 20% in the 20(R)-ginsenoside Rg3- and 20(S)-ginsenoside Rg3-treated group, respectively. From the data in Table II, it was found that the level of DNA methylation was decreased at the promoter region of P53 and BCL2 in cells treated with 20(S)-ginsenoside Rg3, and that the gene expression of P53 was increased, whereas that of BCL2 was decreased. The level of DNA methylation was increased in the promoter region of VEGF and decreased in that of P53 upon treatment with 20(R)-ginsenoside Rg3. In addition, the gene expression of VEGF was decreased, whereas that of P53 was increased. These results indicated that gene expression was not only associated with the level of DNA methylation, but was also associated with specific sites in the promoter region of the gene.

**DNMT1 is upregulated, and DNMT3a and DNMT3b are downregulated by ginsenoside Rg3.** The expression levels of DNMTs are closely linked to DNA methylation patterns. To investigate the molecular mechanism of cytosine methylation induced by ginsenoside Rg3, the mRNA levels of DNMT1, DNMT3a and DNAMT3b were measured using RT-qPCR.

### Table II. MspI/HpaII polymerase chain reaction assay.

| Gene | Primers used | Position of CCGG site (bp) | R-Rg3 | S-Rg3 |
|------|--------------|-----------------------------|-------|-------|
| Bcl2 | XZ-82/XZ-83  | 1701-1704; 1715-1718        | 0     | 0     |
| Bcl2 | XZ-84/XZ-85  | 1903-1906                   | 0     | 0     |
| Bcl2 | XZ-86/XZ-87  | 1977-1980; 1982-1985; 2000-2003 | 1 | 1 |
| Bcl2 | XZ-88/XZ-89  | 2141-2144                   | 0     | 0     |
| Bcl2 | XZ-90/XZ-91  | 2176-2179; 2181-2184; 2198-2199; 2225-2228 | 0 | 2 |
| Bcl2 | XZ-94/XZ-95  | 2371-2374                   | 2     | 0     |
| Bcl2 | XZ-96/XZ-97  | 2673-2676; 2689-2692         | 0     | 0     |
| Bcl2 | XZ-98/XZ-99  | 2844-2947                   | 0     | 0     |
| Bcl2 | XZ-100/XZ-101 | 2946-2949                 | 1     | 2     |
| Bcl2 | XZ-102/XZ-103 | 3095-3098                 | 0     | 0     |
| Bcl2 | XZ-104/XZ-105 | 3163-3166                 | 2     | 0     |
| Bcl2 total | |                       | 1: 18% | 1: 9% |
| VEGF | XZ-106/XZ-107 | 1435-1438                  | 2     | 1     |
| VEGF | XZ-110/XZ-111 | 1981-1984                  | 0     | 0     |
| VEGF | XZ-112/XZ-113 | 2120-2123                  | 0     | 0     |
| VEGF | XZ-114/XZ115 | 2225-2228                   | 0     | 0     |
| VEGF | XZ-116/XZ-117 | 2275-2278; 2285-2288; 2299-2302 | 1 | 1 |
| VEGF | XZ-118/XZ-119 | 2384-2385                  | 1     | 0     |
| VEGF | XZ-120/XZ-121 | 2512-2515                  | 2     | 2     |
| VEGF total | |                       | 1: 42% | 1: 29% |
| P53  | XZ-162/XZ163 | 4928-4931                   | 0     | 1     |
| P53  | XZ-164/XZ-165 | 5108-5111                  | 2     | 2     |
| P53  | XZ-168/XZ-169 | 5476-5479                  | 1     | 0     |
| P53  | XZ-170/XZ-171 | 5641-5644                  | 0     | 2     |
| P53  | XZ-172/XZ-173 | 5675-5678                  | 2     | 0     |
| P53  | XZ-174/XZ-175 | 5717-5720                  | 0     | 0     |
| P53  | XZ-176-XZ-177 | 5831-5834                  | 0     | 0     |
| P53 total | |                       | 1: 14% | 1: 14% |
| Overall total | |                       | 1: 24% | 1: 16% |

0, unchanged; 1, methylation; 2, demethylation; Bcl2, B cell lymphoma 2, VEGF, vascular endothelial growth factor.
Figure 6. Effect of ginsenoside Rg3 on the expression of DNMT1 and DNMT3. *P<0.05 and **P<0.01, vs. untreated control. DNMT, DNA methyltransferase.

**Discussion**

Several reports have demonstrated that ginsenoside Rg3 has pharmacological actions through regulating gene expression (25). In the present study, the CCK8 data showed that the ability of 20(S)-ginsenoside Rg3 to inhibit HepG2 cell growth was more marked, compared with that of 20(R)-ginsenoside Rg3. The HPLC assay also demonstrated that 20(S)-ginsenoside Rg3 induced a more marked reduction in global DNA methylation, compared with 20(R)-ginsenoside Rg3. DNA hypomethylation has been reported in hepatocellular carcinoma and hypomethylation is associated with DNA damage, the promotion of carcinogenesis and activation of tumor suppressor genes (16). Thus, DNA hypomethylation induced by ginsenoside Rg3, particularly 20(S)-ginsenoside Rg3, may be responsible for the inhibition of HepG2 cell proliferation.
The present study further investigated the effect of ginsenoside Rg3 on the methylation of the promoter regions of specific genes. In total, three genes were selected, which are closely associated with tumor angiogenesis, growth and apoptosis. P53 is important in apoptosis, genomic stability and the inhibition of angiogenesis, and its expression is increased by ginsenoside-Rg3 treatment (26). VEGF stimulates vascularogenesis and angiogenesis. The overexpression of VEGF can cause vascular disease and the development of cancer. A decrease in its expression is induced by 20-ginsenoside Rg3 (23). Bcl2 inhibits cell apoptosis and is classified as an oncogene. The expression was increased by 20-ginsenoside Rg3 (5). Classically, hypermethylation of the promoter region is associated with gene silencing, and hypomethylation of the promoter region is correlated with gene activation. In the present study, it was found that hypomethylation of the promoter region of P53 was consistent with gene activation. DNA methylation of the promoter regions of BCL2 were unchanged or decreased, however, the methylated sites of the promoter region and the gene expression were altered, suggesting that the DNA methylation level and the specific methylated site of the promoter region may be important for gene expression.

DNMTs are responsible for continued and de novo DNA methylation. DNMT1 maintains the DNA methylation status by maintaining the transfer of methyl groups to the newly synthesized DNA strands during DNA replication. DNMT3a and DNMT3b introduce the novel methylated cytosine site to the unmodified cytosine residues. Oh et al. (27) reported that the DNA methylation and expression of DNMT1, DNMT3a and DNMT3b were higher in hepatocellular carcinoma, compared with those in normal liver tissue. In the present study, it was found that treatment with ginsenoside Rg3 increased the relative mRNA levels of DNMT1, but significantly reduced the levels of DNMT3a and DNMT3b. Therefore, low expression levels of DNMT3a and DNMT3b may account for decreased methylation, although high levels of DNMT1 expressed during DNA replication maintained the methylation pattern. 20(S)-Ginsenoside Rg3 and 20(R)-ginsenoside Rg3 have exhibited stereo-specific effects in several studies. For example, Kim et al. (19) showed that 20(R)-ginsenoside Rg3 regulates the expression of multiple genes during the initiation of the transforming growth factor-β1-induced epithelial-mesenchymal transition and suppresses lung cancer development, whereas 20(S)-ginsenoside Rg3 does not. Park et al. (20) showed that 20(S)-ginsenoside Rg3 has more potent anticancer activity, compared with 20(R)-ginsenoside Rg3 in inducing human gastric cancer cell apoptosis. In the present study, 20(S)-ginsenoside Rg3 exhibited more potent antiproliferative effects on HepG2 cells and induced a more marked reduction in the methylation of global DNA and CpG islands, compared with 20(R)-ginsenoside Rg3, and reduced the expression levels of DNMT3a and DNMT3b. Thus, the different ginsenoside Rg3 epimers exhibit different stereo-specific effects in different types of cell, and selection of the appropriate epimer is required for treating different diseases.

In conclusion, data obtained in the present study indicated that ginsenoside Rg3 inhibited HepG2 cell proliferation in a dose-dependent manner, induced a reduction in the methylation of global genomic DNA and, for a promoter region of a specific gene, upregulated the expression of DNMT1 and downregulated the expression of DNMT3a and DNMT3b. In addition, 20(S)-ginsenoside Rg3 exhibited superior biological activity, compared with 20(S)-ginsenoside Rg3. These data indicated that 20(S)-ginsenoside Rg3 may offer increased potential, compared with 20(R)-ginsenoside Rg3, as an adjuvant treatment for hepatocellular carcinoma.

Acknowledgements

The authors would like to thank the National Natural Science Foundation of China (grant no. 31200953) and the China Postdoctoral Science Foundation Funded Project (grant no. 2013M530977) for financial support.

References

1. Shan X, Fu YS, Aziz F, Wang XQ, Yan Q and Liu JW: Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation. PLoS One 9: e115401, 2014.
2. Joo EJ, Chun J, Ha YW, Ko HJ, Xu MY and Kim YS: Novel roles of ginsenoside Rg3 in apoptosis through downregulation of epidermal growth factor receptor. Chem Biol Interact 233: 25-34, 2015.
3. Shan X, Tian LL, Zhang YM, Wang XQ, Yan Q and Liu JW: Ginsenoside Rg3 suppresses FUT4 expression through inhibiting NF-κB/p65 signaling pathway to promote melanoma cell death. Int J Oncol 47: 701-709, 2015.
4. Zeng D, Wang J, Kong P, Chang C, Li J and Li J: Ginsenoside Rg3 inhibits HIF-1α and VEGF expression in patient with acute leukemia via inhibiting the activation of PI3K/Akt and ERK1/2 pathways. Int J Clin Exp Pathol 7: 2717-2728, 2014.
5. Luo Y, Zhang P, Zeng HQ, Lou SF and Wang DX: Ginsenoside Rg3 induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein. Mol Med Rep 12: 3557-3562, 2015.
6. Ge X, Zhen F, Yang B, Yang X, Cai J, Zhang C, Zhang S, Cao Y, Ma J, Cheng H and Sun X: Ginsenoside Rg3 enhances radiosensitization of hypoxic oesophageal cancer cell lines through vascular endothelial growth factor and hypoxia inducible factor 1α. Int J Med Res 42: 628-640, 2014.
7. Kim JH, Cho SY, Lee JH, Jeong SM, Yoon IS, Lee BH, Lee JH, Pyo MK, Lee SM, Chung JM, et al: Neuroprotective effects of ginsenoside Rg3 against homocysteine-induced excitotoxicity in rat hippocampus. Brain Res 1136: 190-199, 2007.
8. Yoon SJ, Park JY, Choi S, Lee JB, Jung H, Kim TD, Yoon SR, Choi I, Shim S and Park YJ: Ginsenoside Rg3 regulates S-nitrosylation of the NLRP3 inflammasome via suppression of iNOS. Biochem Biophys Res Commun 463: 1184-1189, 2015.
9. Paska AV and Hudler P: Aberrant methylation patterns in cancer: A clinical view. Biochem Med (Zagreb) 25: 161-176, 2015.
10. Poke FS, Qadi A and Holloway AF: Reversing aberrant methylation patterns in cancer. Curr Med Chem 17: 1246-1254, 2010.
11. Price RJ, Lillycrop KA and Burdge GC: Folic acid supplementation in vitro induces cell type-specific changes in BRCA1 and BRCA2 mRNA expression, but does not alter DNA methylation of their promoters or DNA repair. Nutr Res 35: 532-544, 2015.
12. Gadgil MS, Joshi KS, Naik SS, Pandit AN, Otvír SR and Patwardhan BK: Association of homocysteine with global DNA methylation in vegetarian Indian pregnant women and neonatal birth anthropometrics. J Matern Fetal Neonatal Med 27: 1749-1753, 2014.
13. Sie KK, Li J, Ly A, Sohn KJ, Croxford R and Kim YJ: Effect of maternal and postweaning folic acid supplementation on birth anthropometrics. J Matern Fetal Neonatal Med 27: 1136-1140, 2014.
14. Sciusci EL, Loose DS and Wray CJ: Clinical implications of DNA methylation in hepatocellular carcinoma. HPB (Oxford) 13: 369-376, 2011.
16. Nishida N and Kudo M: Alteration of epigenetic profile in human hepatocellular carcinoma and its clinical implications. Liver Cancer 3: 417-427, 2014.

17. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

18. Wu R, Ru Q, Chen L, Ma B and Li C: Stereospecificity of ginsenoside Rg3 in the promotion of cellular immunity in hepatoma H22-bearing mice. J Food Sci 79: H1430-H1435, 2014.

19. Kim YJ, Choi WI, Jeon BN, Choi KC, Kim K, Kim TJ, Ham J, Jang HJ, Kang KS and Ko H: Stereospecific effects of ginsenoside 20-Rg3 inhibits TGF-β1-induced epithelial-mesenchymal transition and suppresses lung cancer migration, invasion and anoikis resistance. Toxicology 322: 23-33, 2014.

20. Park EH, Kim YJ, Yamabe N, Park SH, Kim HK, Jang HJ, Kim JH, Cheon GJ, Ham J and Kang KS: Stereospecific anticancer effects of ginsenoside Rg3 epimers isolated from heat-processed American ginseng on human gastric cancer cell. J Ginseng Res 38: 22-27, 2014.

21. Cheong JH, Kim H, Hong MJ, Yang MH, Kim JW, Yoo H, Yang H, Park JH, Sung SH, Kim HP and Kim J: Stereoisomer-specific anticancer activities of ginsenoside Rg3 and Rh2 in HepG2 cells: Disparity in cytotoxicity and autophagy-inducing effects due to 20(S)-epimers. Biol Pharm Bull 38: 102-108, 2015.

22. Fragou D, Zanos P, Koudou S, Njau S, Kitchen I, Bailey A and Kovatsi L: Effect of chronic heroin and cocaine administration on global DNA methylation in brain and liver. Toxicol Lett 218: 260-265, 2013.

23. Zhou B, Wang J and Yan Z: Ginsenoside Rg3 attenuates hepatoma VEGF overexpression after hepatic artery embolization in an orthotopic transplantation hepatocellular carcinoma rat model. Onco Targets Ther 7: 1945-1954, 2014.

24. Yuan HD, Quan HY, Zhang Y, Kim SH and Chung SH: 20(S)-Ginsenoside Rg3-induced apoptosis in HT-29 colon cancer cells is associated with AMPK signaling pathway. Mol Med Rep 3: 825-831, 2010.

25. Lu JM, Yao Q and Chen C: Ginseng compounds: An update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 7: 293-302, 2009.

26. Zhang F, Li M, Wu X, Hu Y, Cao Y, Wang X, Xiang S, Li H, Jiang L, Tan Z, et al: 20(S)-ginsenoside Rg3 promotes senescence and apoptosis in gallbladder cancer cells via the p53 pathway. Drug Des Devel Ther 9: 3969-3987, 2015.

27. Oh BK, Kim H, Park HJ, Shim YH, Choi J, Park C and Park YN: DNA methyltransferase expression and DNA methylation in human hepatocellular carcinoma and their clinicopathological correlation. Int J Mol Med 20: 65-73, 2007.